Dose-dependent Response of FGF-2 for Lymphangiogenesis

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2004 Aug 4

PMID 15289610

Citations 116

Authors

Lynn K Chang

Guillermo Garcia-Cardena

Filip Farnebo

Michael Fannon

Emy J Chen

Catherine Butterfield

Marsha A Moses

Richard C Mulligan

Judah Folkman

Arja Kaipainen

Affiliations

Soon will be listed here.

Abstract

Spatio-temporal studies on the growth of capillary blood vessels and capillary lymphatic vessels in tissue remodeling have suggested that lymphangiogenesis is angiogenesis-dependent. We revisited this concept by using fibroblast growth factor 2 (FGF-2) (80 ng) to stimulate the growth of both vessel types in the mouse cornea. When we lowered the dose of FGF-2 in the cornea 6.4-fold (12.5 ng), the primary response was lymphangiogenic. Further investigation revealed that vascular endothelial growth factor-C and -D are required for this apparent lymphangiogenic property of FGF-2, and when the small amount of accompanying angiogenesis was completely suppressed, lymphangiogenesis remained unaffected. Our findings demonstrate that there is a dose-dependent response of FGF-2 for lymphangiogenesis, and lymphangiogenesis can occur in the absence of a preexisting or developing vascular bed, i.e., in the absence of angiogenesis, in the mouse cornea.

Citing Articles

Research progress on the correlation between corneal neovascularization and lymphangiogenesis (Review).

Zhang Z, Zhao R, Wu X, Ma Y, He Y Mol Med Rep. 2024; 31(2).

PMID: 39635819 PMC: 11638739. DOI: 10.3892/mmr.2024.13412.

Lymphatic system regulation of anti-cancer immunity and metastasis.

Lei P, Fraser C, Jones D, Ubellacker J, Padera T Front Immunol. 2024; 15:1449291.

PMID: 39211044 PMC: 11357954. DOI: 10.3389/fimmu.2024.1449291.

Review of treatment strategies after lymphadenectomy: From molecular therapeutics to immediate microsurgical lymphatic reconstruction.

Sung C, Wang J, Chang J, Wong A J Vasc Surg Venous Lymphat Disord. 2024; 12(5):101844.

PMID: 38316291 PMC: 11523459. DOI: 10.1016/j.jvsv.2024.101844.

Molecular and metabolic orchestration of the lymphatic vasculature in physiology and pathology.

Montenegro-Navarro N, Garcia-Baez C, Garcia-Caballero M Nat Commun. 2023; 14(1):8389.

PMID: 38104163 PMC: 10725466. DOI: 10.1038/s41467-023-44133-x.

Dual gene-activated dermal scaffolds regulate angiogenesis and wound healing by mediating the coexpression of VEGF and angiopoietin-1.

Weng T, Yang M, Zhang W, Jin R, Xia S, Zhang M Bioeng Transl Med. 2023; 8(5):e10562.

PMID: 37693053 PMC: 10487340. DOI: 10.1002/btm2.10562.

References

St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View

Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y . Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997; 16(13):3898-911. PMC: 1170014. DOI: 10.1093/emboj/16.13.3898. View

Oh S, Jeltsch M, Birkenhager R, McCarthy J, Weich H, Christ B . VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997; 188(1):96-109. DOI: 10.1006/dbio.1997.8639. View

Singer A, Clark R . Cutaneous wound healing. N Engl J Med. 1999; 341(10):738-46. DOI: 10.1056/NEJM199909023411006. View

Dor Y, Djonov V, Abramovitch R, Itin A, Fishman G, Carmeliet P . Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002; 21(8):1939-47. PMC: 125962. DOI: 10.1093/emboj/21.8.1939. View

Kuo C, Farnebo F, Yu E, Christofferson R, Swearingen R, Carter R . Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 2001; 98(8):4605-10. PMC: 31881. DOI: 10.1073/pnas.081615298. View

Cursiefen C, Chen L, Borges L, Jackson D, Cao J, Radziejewski C . VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004; 113(7):1040-50. PMC: 379325. DOI: 10.1172/JCI20465. View

Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, Sorokin L, Alitalo K, Jackson D . Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci. 2002; 43(7):2127-35. View

Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J . Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res. 2004; 94(5):664-70. DOI: 10.1161/01.RES.0000118600.91698.BB. View

10.

Kenyon B, Voest E, Chen C, Flynn E, Folkman J, DAmato R . A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996; 37(8):1625-32. View

11.

Chang L, Kaipainen A, Folkman J . Lymphangiogenesis new mechanisms. Ann N Y Acad Sci. 2003; 979:111-9. DOI: 10.1111/j.1749-6632.2002.tb04872.x. View

12.

Fannon M, Nugent M . Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem. 1996; 271(30):17949-56. DOI: 10.1074/jbc.271.30.17949. View

13.

Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova T . Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 2001; 20(6):1223-31. PMC: 145532. DOI: 10.1093/emboj/20.6.1223. View

14.

Baldwin M, Catimel B, Nice E, Roufail S, Hall N, Stenvers K . The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J Biol Chem. 2001; 276(22):19166-71. DOI: 10.1074/jbc.M100097200. View

15.

Veikkola T, Alitalo K . VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999; 9(3):211-20. DOI: 10.1006/scbi.1998.0091. View

16.

Kisker O, Becker C, Prox D, Fannon M, Damato R, Flynn E . Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001; 61(20):7669-74. View

17.

Fabian G . Investigations on the uterine lymphatics of juvenile mice, up to the onset of sexual maturity. Lymphology. 1978; 11(3):123-6. View

18.

Skobe M, Hawighorst T, Jackson D, Prevo R, Janes L, Velasco P . Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001; 7(2):192-8. DOI: 10.1038/84643. View

19.

Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E . A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996; 15(2):290-98. PMC: 449944. View

20.

Karkkainen M, Ferrell R, Lawrence E, Kimak M, Levinson K, McTigue M . Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000; 25(2):153-9. DOI: 10.1038/75997. View